Documentos relacionados

1. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
2. Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells.
3. Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-α in patients with chronic hepatitis B.
4. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
5. [Precise immunological classification guidance for early initiation of antiviral therapy in patients with chronic HBV infection].
6. [Research progress on novel antiviral therapeutic drugs for chronic hepatitis B].
7. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
8. Genetic variation in STAT4 is associated with treatment response to pegylated interferon in patients with chronic hepatitis B.
9. Adenoviral gene therapy for bladder cancer.
10. A genetic variant of <i>CXCR4</i> predicts pegylated interferon-alpha treatment response in HBeAg-positive chronic hepatitis B patients.